These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 836242)

  • 41. Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options.
    Flanagan BA; Collins C; Parra S
    Cutis; 2012 Feb; 89(2):69-72. PubMed ID: 22474728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Management of epistaxis in Rendu-Osler-Weber disease].
    Morales Salas M; Ventura J; Ruiz Carmona E; Muñoz F
    An Otorrinolaringol Ibero Am; 2001; 28(3):281-91. PubMed ID: 11455885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using the KTP/532 laser to control epistaxis in patients with hereditary hemorrhagic telangiectasia.
    Vickery CL; Kuhn FA
    South Med J; 1996 Jan; 89(1):78-80. PubMed ID: 8545698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study.
    Fang J; Chen X; Zhu B; Ye H; Zhang W; Guan J; Su K
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):217-221. PubMed ID: 28418273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surgical management of life-threatening epistaxis in Osler-Weber-Rendu disease.
    Rebeiz EE; Bryan DJ; Ehrlichman RJ; Shapshay SM
    Ann Plast Surg; 1995 Aug; 35(2):208-13. PubMed ID: 7486747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease.
    Folz BJ; Tennie J; Lippert BM; Werner JA
    Rhinology; 2005 Mar; 43(1):40-6. PubMed ID: 15844501
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia.
    Zarrabeitia R; Ojeda-Fernandez L; Recio L; Bernabéu C; Parra JA; Albiñana V; Botella LM
    Thromb Haemost; 2016 Jun; 115(6):1167-77. PubMed ID: 26818701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Percutaneous embolization to control epistaxis in Rendu-Osler-Weber disease.
    Strother CM; Newton TH
    Arch Otolaryngol; 1976 Jan; 102(1):58-60. PubMed ID: 1244834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia.
    Yin LX; Reh DD; Hoag JB; Mitchell SE; Mathai SC; Robinson GM; Merlo CA
    Laryngoscope; 2016 May; 126(5):1029-32. PubMed ID: 26393959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu syndrome).
    Santos MA
    J Gen Intern Med; 2017 Feb; 32(2):218-219. PubMed ID: 27714648
    [No Abstract]   [Full Text] [Related]  

  • 51. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia.
    Penaloza A; Vekemans MC; Lambert C; Hermans C
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):616-8. PubMed ID: 21885956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Intractable epistaxis in Osler-Rendu-Weber syndrome].
    Zalagh M; Errami N; Bouaity B; Hemmaoui B; Itoua W; Benariba F
    Rev Stomatol Chir Maxillofac; 2011 Nov; 112(5):310-2. PubMed ID: 21940027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease) as an example of a rare disease relevant for oto-rhino-laryngology].
    Geisthoff UW; Maune S; Schneider G
    Laryngorhinootologie; 2011 Apr; 90(4):230-42; quiz 243-4. PubMed ID: 21523625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Epistaxis-overview and current aspects].
    Thangavelu K; Köhnlein S; Eivazi B; Gurschi M; Stuck BA; Geisthoff U
    HNO; 2021 Nov; 69(11):931-942. PubMed ID: 34643746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hereditary hemorrhagic telangiectasia showing severe anemia which was successfully treated with estrogen.
    Hisada T; Kuwabara H; Tsunoda T; Kaneko K; Kubota S; Miwa Y; Mori M
    Intern Med; 1995 Jun; 34(6):589-92. PubMed ID: 7549150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Morphology and distribution of nasal telangiectasia in HHT-patients with epistaxis.
    Folz BJ; Wollstein AC; Lippert BM; Werner JA
    Am J Rhinol; 2005; 19(1):65-70. PubMed ID: 15794077
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report.
    Mei-Zahav M; Blau H; Bruckheimer E; Zur E; Goldschmidt N
    J Otolaryngol Head Neck Surg; 2017 Oct; 46(1):58. PubMed ID: 28978360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Karnezis TT; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.